-

KARL STORZ Receives Innovative Technology Designation from Vizient for VITOM eagle Exoscope with ARTip CRUISE Motorized Arm

Designation recognizes Vizient-contracted products that bring improvements to healthcare industry

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States proudly announces its VITOM® eagle exoscope with ARTip CRUISE® motorized holding system has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country. KARL STORZ exhibited the VITOM eagle and ARTip CRUISE at this year’s Vizient Innovative Technology Exchange in Las Vegas.

Each year, healthcare experts serving on Vizient provider-led councils review select products and technologies for their potential to enhance clinical care, patient safety, or healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to highlight the potential impact of these innovations on patient care and business models of healthcare organizations.

The VITOM eagle exoscopic system is a 4K/3D/ICG heads-up visualization solution and the only exoscope on the market that enables surgeons to seamlessly switch between exoscopic and endoscopic visualization on a single video platform, the KARL STORZ IMAGE1 S®. VITOM eagle offers exceptional image quality and depth perception for critical surgical interventions.

Designed with the surgeon in mind, the VITOM eagle addresses the growing concern of musculoskeletal disorders caused by non-ergonomic posture during lengthy microsurgical procedures. With a high level of magnification and position flexibility, the VITOM eagle allows a more natural posture during surgery. The ARTip CRUISE motorized, steerable holding arm enhances the user experience by enabling quick, accurate positioning with minimal effort, simplifying workflow and permitting optimal focus and stability throughout the procedure.

The unique combination of the VITOM eagle, ARTip CRUISE, and IMAGE1 S allows hospitals to access advanced imaging via a single platform, lowering equipment downtime, streamlining surgical workflow, and improving cost efficiency.

“We are proud to bring the VITOM eagle exoscope with ARTip technology to the US market, particularly after watching the exoscopic market evolve for almost a decade,” said Chris Smith, Vice President of Sales & Marketing, Upper Endoscopy, at KARL STORZ United States. “We always strive to address the quadruple aim in our solutions—reducing cost, improving quality, increasing physician and care team satisfaction, and enhancing patient outcomes. We’re confident this solution will hit the mark with our clinical end users, providing the ability to truly transform microsurgery and adding many benefits to those seeking to combine the advantages of an operating microscope and an endoscopic visualization platform. The VITOM eagle provides this very unique combination in a cost-effective way.”

“Congratulations to KARL STORZ for achieving this peer-designated status,” said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader. “Our customer council deemed the VITOM eagle exoscope with ARTip CRUISE motorized arm worthy of this designation for its potential to make a real difference in the healthcare industry.”

Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents approximately $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

For more detailed information about the VITOM eagle and ARTip CRUISE technology, visit https://www.karlstorz.com/de/en/imaging-solutions.htm

About KARL STORZ

KARL STORZ is an innovative leader in endoscopic technology and surgical imaging solutions across virtually all surgical specialties. Its integrated OR solutions enhance collaboration to improve clinical efficiency and outcomes inside the hospital and across other sites of care. With subsidiaries around the world, KARL STORZ is a family-owned company based in Germany that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit www.karlstorz.com.

Contacts

Media contact:
Susan Mancia
Marketing Communications
KARL STORZ United States
657-385-5285

KARL STORZ


Release Versions

Contacts

Media contact:
Susan Mancia
Marketing Communications
KARL STORZ United States
657-385-5285

Social Media Profiles
More News From KARL STORZ

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom